A T cell redirection platform for co-targeting dual antigens on solid tumors

References

• Nelson MH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev. 2015;263(1):90–19. doi:10.1111/imr.12245.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Murray JC, Shuptrine CW. Antibody-based immunotherapy of cancer. Cell. 2012;148(6):1081–84. doi:10.1016/j.cell.2012.02.034.
   PubMed Web of Science ®Google Scholar
• Strohl WR, Naso M. Bispecific T-Cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies (Basel). 2019;8(3). doi:10.3390/antib8030041.
   PubMedGoogle Scholar
• Slaney CY, Wang P, Darcy PK, Kershaw MH. CARs versus BiTEs: a comparison between T Cell-redirection strategies for cancer treatment. Cancer Discov. 2018;8(8):924–34. doi:10.1158/2159-8290.CD-18-0297.
   PubMed Web of Science ®Google Scholar
• Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33–51. doi:10.2147/BTT.S166310.
   PubMed Web of Science ®Google Scholar
• Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48:7022–32.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–12. doi:10.1038/onc.2008.271.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–26. doi:10.1158/2159-8290.CD-18-0442.
   PubMed Web of Science ®Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Ol C, others, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212–17. doi:10.1073/pnas.1320318110.
   PubMed Web of Science ®Google Scholar
• Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–35. doi:10.1038/nature14404.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. doi:10.3389/fimmu.2019.00168.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–47. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Wu Z, Cheung NV. T cell engaging bispecific antibody (T-BsAb): from technology to therapeutics. Pharmacol Ther. 2018;182:161–75. doi:10.1016/j.pharmthera.2017.08.005.
   PubMed Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102–17. doi:10.1016/j.ymeth.2018.10.026.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, others, et al. FDA approval: blinatumomab. Clin Cancer Res. 2015;21(18):4035–39. doi:10.1158/1078-0432.CCR-15-0612.
   PubMed Web of Science ®Google Scholar
• Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010;2(2):129–36. doi:10.4161/mabs.2.2.11221.
   PubMed Web of Science ®Google Scholar
• Runcie K, Budman DR, John V, Seetharamu N. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics. Mol Med. 2018;24(1):50. doi:10.1186/s10020-018-0051-4.
   PubMedGoogle Scholar
• Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D and others, et al. Membrane-Proximal epitope facilitates efficient T Cell synapse formation by Anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383–95. doi:10.1016/j.ccell.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother. 2010;59(8):1197–209. doi:10.1007/s00262-010-0844-y.
   PubMed Web of Science ®Google Scholar
• Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402–08.
   PubMed Web of Science ®Google Scholar
• Mabry R, Snavely M. Therapeutic bispecific antibodies: the selection of stable single-chain fragments to overcome engineering obstacles. IDrugs. 2010;13:543–49.
   PubMedGoogle Scholar
• Quintero-Hernández V, Juárez-González VR, Ortíz-León M, Sánchez R, Possani LD, Becerril B. The change of the scFv into the fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodies. Mol Immunol. 2007;44(6):1307–15. doi:10.1016/j.molimm.2006.05.009.
   PubMed Web of Science ®Google Scholar
• Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol. 2001;305(5):989–1010. doi:10.1006/jmbi.2000.4265.
   PubMed Web of Science ®Google Scholar
• Leung KK, Wilson GM, Kirkemo LL, Riley NM, Coon JJ, Wells JA. Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes. Proc Natl Acad Sci U S A. 2020;117(14):7764–75. doi:10.1073/pnas.1917947117.
   PubMed Web of Science ®Google Scholar
• Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990;87(21):8602–06. doi:10.1073/pnas.87.21.8602.
   PubMed Web of Science ®Google Scholar
• Collins MA, Bednar F, Zhang Y, Brisset JC, Galbán S, Galbán CJ, Rakshit S, Flannagan KS, Adsay NV, Pasca Di Magliano M. Oncogenic kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012;122(2):639–53. doi:10.1172/JCI59227.
   PubMed Web of Science ®Google Scholar
• Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Mj E, others, et al. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018;7. doi:10.7554/eLife.31098.
   Google Scholar
• Roskopf CC, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS. Dual-targeting triplebody 33- 3-19mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells. Oncotarget. 2016;7(16):22579–89. doi:10.18632/oncotarget.8022.
   PubMedGoogle Scholar
• Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C, Guo Y, Guo B, Ti D. Han X and others. Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. J Hematol Oncol. 2019;12(1):57. doi:10.1186/s13045-019-0741-6.
   PubMedGoogle Scholar
• Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, Gustafsson K, Anderson J. Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol Ther. 2017;25(5):1234–47. doi:10.1016/j.ymthe.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. Precision tumor recognition by T Cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–79. doi:10.1016/j.cell.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, others, et al. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun. 2019;10(1):5387. doi:10.1038/s41467-019-13196-0.
   PubMedGoogle Scholar
• Zheng S, Moores S, Jarantow S, Pardinas J, Chiu M, Zhou H, Wang W. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. MAbs. 2016;8(3):551–61. doi:10.1080/19420862.2015.1136762.
   PubMed Web of Science ®Google Scholar
• Slaga D, Ellerman D, Lombana TN, Vij R, Li J, Hristopoulos M, Clark R, Johnston J, Shelton A, Mai E, others, et al. Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3. Sci Transl Med. 2018;10(463). doi:10.1126/scitranslmed.aat5775.
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J Immunol Methods. 2002;267(2):213–26. doi:10.1016/S0022-1759(02)00148-5.
   PubMed Web of Science ®Google Scholar
• Persson H, Ye W, Wernimont A, Adams JJ, Koide A, Koide S, Lam R, Ss S. CDR-H3 diversity is not required for antigen recognition by synthetic antibodies. J Mol Biol. 2013;425(4):803–11. doi:10.1016/j.jmb.2012.11.037.
   PubMed Web of Science ®Google Scholar
• Himanen JP, Yermekbayeva L, Janes PW, Walker JR, Xu K, Atapattu L, Rajashankar KR, Mensinga A, Lackmann M, Db N, others, et al. Architecture of Eph receptor clusters. Proc Natl Acad Sci U S A. 2010;107(24):10860–65. doi:10.1073/pnas.1004148107.
   PubMed Web of Science ®Google Scholar
• Birtalan S, Zhang Y, Fellouse FA, Shao L, Schaefer G, Sidhu SS. The intrinsic contributions of tyrosine, serine, glycine and arginine to the affinity and specificity of antibodies. J Mol Biol. 2008;377(5):1518–28. doi:10.1016/j.jmb.2008.01.093.
   PubMed Web of Science ®Google Scholar
• Lobo NC, Gedye C, Apostoli AJ, Brown KR, Paterson J, Stickle N, Robinette M, Fleshner N, Hamilton RJ, Kulkarni G, others, et al. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine. BMC Cancer. 2016;16(1):485. doi:10.1186/s12885-016-2539-z.
   PubMedGoogle Scholar
• Nixon AML, Duque A, Yelle N, McLaughlin M, Davoudi S, Pedley NM, Haynes J, Brown KR, Pan J, Hart T, others, et al. A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations. Sci Rep. 2019;9(1):842. doi:10.1038/s41598-018-37462-1.
   PubMedGoogle Scholar
• Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Brown KR, Jaksani S, Overmeer R, others, et al. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med. 2017;23(1):60–68. doi:10.1038/nm.4219.
   PubMed Web of Science ®Google Scholar
• Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308. doi:10.1038/nprot.2013.143.
   PubMed Web of Science ®Google Scholar
• Fu X, Tao L, Rivera A, Williamson S, Song XT, Ahmed N, Zhang X. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS One. 2010;5(7):e11867. doi:10.1371/journal.pone.0011867.
   PubMed Web of Science ®Google Scholar
• Hammond SA, Lutterbuese R, Roff S, Lutterbuese P, Schlereth B, Bruckheimer E, Kinch MS, Coats S, Baeuerle PA, Kufer P, others, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 2007;67(8):3927–35. doi:10.1158/0008-5472.CAN-06-2760.
   PubMed Web of Science ®Google Scholar
• Li N, Liu S, Sun M, Chen W, Xu X, Zeng Z, Tang Y, Dong Y, Chang AH, Zhao Q. Chimeric antigen receptor-modified T Cells redirected to EphA2 for the immunotherapy of non-small cell lung cancer. Transl Oncol. 2018;11(1):11–17. doi:10.1016/j.tranon.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Iwahori K, Kakarla S, Velasquez MP, Yu F, Yi Z, Gerken C, Song XT, Gottschalk S. Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther. 2015;23(1):171–78. doi:10.1038/mt.2014.156.
   PubMed Web of Science ®Google Scholar
• Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, others, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol. 2006;43(8):1129–43. doi:10.1016/j.molimm.2005.07.034.
   PubMed Web of Science ®Google Scholar
• Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, others, et al. Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells. PLoS One. 2010;5(10):e13474. doi:10.1371/journal.pone.0013474.
   PubMed Web of Science ®Google Scholar
• Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, Wicha MS, Chang AE, Li Q. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 2013;149(1):156–68. doi:10.1016/j.clim.2013.07.006.
   PubMed Web of Science ®Google Scholar
• Ma X, Barthelemy PA, Rouge L, Wiesmann C, Sidhu SS. Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor. J Mol Biol. 2013;425(12):2247–59. doi:10.1016/j.jmb.2013.03.020.
   PubMed Web of Science ®Google Scholar
• Mudali SV, Fu B, Lakkur SS, Luo M, Embuscado EE, Iacobuzio-Donahue CA. Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis. 2006;23(7–8):357–65. doi:10.1007/s10585-006-9045-7.
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004;23(7):1448–56. doi:10.1038/sj.onc.1207247.
   PubMed Web of Science ®Google Scholar
• Pw J, Griesshaber B, Atapattu L, Nievergall E, Ll H, Mensinga A, Chheang C, Bw D, Aw B, Pi B, others, et al. Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. J Cell Biol. 2011;195(6):1033–45. doi:10.1083/jcb.201104037.
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Esaki K, Birtalan S, Raptis D, Cancasci VJ, Koide A, Jhurani P, Vasser M, Wiesmann C, Aa K, others, et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J Mol Biol. 2007;373(4):924–40. doi:10.1016/j.jmb.2007.08.005.
   PubMed Web of Science ®Google Scholar
• Miersch S, Kuruganti S, Walter MR, Sidhu SS. A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family. Protein Eng Des Sel. 2017;30(9):697–704. doi:10.1093/protein/gzx048.
   PubMed Web of Science ®Google Scholar
• Pollock SB, Hu A, Mou Y, Martinko AJ, Julien O, Hornsby M, Ploder L, Adams JJ, Geng H, Müschen M, others, et al. Highly multiplexed and quantitative cell-surface protein profiling using genetically barcoded antibodies. Proc Natl Acad Sci U S A. 2018;115(11):2836–41. doi:10.1073/pnas.1721899115.
   PubMed Web of Science ®Google Scholar
• Tao Y, Mis M, Blazer L, Ustav M, Steinhart Z, Chidiac R, Kubarakos E, O’Brien S, Wang X, Jarvik N, others, et al. Tailored tetravalent antibodies potently and specifically activate Wnt/frizzled pathways in cells, organoids and mice. Elife. 2019;8. doi:10.7554/eLife.46134.
   Google Scholar
• Ward ES, Güssow D, Griffiths AD, Jones PT, Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from escherichia coli. Nature. 1989;341(6242):544–46. doi:10.1038/341544a0.
   PubMed Web of Science ®Google Scholar
• Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: where are we now?. World J Gastroenterol. 2018;24(20):2137–51. doi:10.3748/wjg.v24.i20.2137.
   PubMed Web of Science ®Google Scholar
• Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, Quinones L, Sela Y, Yamazoe T, Gordon N, others, et al. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). J Clin Invest. 2019;129(9):3594–609. doi:10.1172/JCI127755.
   PubMed Web of Science ®Google Scholar
• Wu B, Wang S, De SK, Barile E, Quinn BA, Zharkikh I, Purves A, Stebbins JL, Oshima RG, Pb F, others, et al. Design and characterization of novel EphA2 agonists for targeted delivery of chemotherapy to cancer cells. Chem Biol. 2015;22(7):876–87. doi:10.1016/j.chembiol.2015.06.011.
   PubMedGoogle Scholar
• Topp MS, Gökbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, Viardot A, Marks R, Diedrich H, Faul C, others, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134–40. doi:10.1200/JCO.2014.56.3247.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Sf L, others, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, others, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25. doi:10.1126/scitranslmed.3008226.
   PubMed Web of Science ®Google Scholar
• Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods. 2014;65:95–104.
   PubMed Web of Science ®Google Scholar
• Himanen JP. Ectodomain structures of Eph receptors. Semin Cell Dev Biol. 2012;23(1):35–42. doi:10.1016/j.semcdb.2011.10.025.
   PubMed Web of Science ®Google Scholar
• Chavent M, Seiradake E, Jones EY, Sansom MS. Structures of the EphA2 receptor at the membrane: role of lipid interactions. Structure. 2016;24(2):337–47. doi:10.1016/j.str.2015.11.008.
   PubMed Web of Science ®Google Scholar
• Zah E, Nam E, Bhuvan V, Tran U, Ji BY, Gosliner SB, Wang X, Brown CE, Chen YY. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11(1):2283. doi:10.1038/s41467-020-16160-5.
   PubMed Web of Science ®Google Scholar